JP2024534488A5 - - Google Patents
Info
- Publication number
- JP2024534488A5 JP2024534488A5 JP2024517157A JP2024517157A JP2024534488A5 JP 2024534488 A5 JP2024534488 A5 JP 2024534488A5 JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024534488 A5 JP2024534488 A5 JP 2024534488A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- target
- effective dose
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245162P | 2021-09-16 | 2021-09-16 | |
| US63/245,162 | 2021-09-16 | ||
| US202163250177P | 2021-09-29 | 2021-09-29 | |
| US63/250,177 | 2021-09-29 | ||
| US202163293619P | 2021-12-23 | 2021-12-23 | |
| US63/293,619 | 2021-12-23 | ||
| US202263348876P | 2022-06-03 | 2022-06-03 | |
| US63/348,876 | 2022-06-03 | ||
| PCT/US2022/076516 WO2023044398A1 (en) | 2021-09-16 | 2022-09-15 | Dosing of muscle targeting complexes for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534488A JP2024534488A (ja) | 2024-09-20 |
| JP2024534488A5 true JP2024534488A5 (https=) | 2025-09-25 |
Family
ID=85603633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517157A Pending JP2024534488A (ja) | 2021-09-16 | 2022-09-15 | ジストロフィノパチーを処置するための筋標的化複合体の投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250018050A1 (https=) |
| EP (1) | EP4401777A4 (https=) |
| JP (1) | JP2024534488A (https=) |
| KR (1) | KR20240058160A (https=) |
| AU (1) | AU2022345986A1 (https=) |
| CA (1) | CA3230451A1 (https=) |
| IL (1) | IL311507A (https=) |
| MX (1) | MX2024003373A (https=) |
| WO (1) | WO2023044398A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025255283A1 (en) * | 2024-06-07 | 2025-12-11 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140329762A1 (en) * | 2013-03-15 | 2014-11-06 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| CN109462995A (zh) * | 2016-05-04 | 2019-03-12 | 波涛生命科学有限公司 | 生物活性剂的方法和组合物 |
| US20190330626A1 (en) * | 2016-07-15 | 2019-10-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for use in dystrophin transcript |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
-
2022
- 2022-09-15 EP EP22870961.4A patent/EP4401777A4/en active Pending
- 2022-09-15 WO PCT/US2022/076516 patent/WO2023044398A1/en not_active Ceased
- 2022-09-15 CA CA3230451A patent/CA3230451A1/en active Pending
- 2022-09-15 IL IL311507A patent/IL311507A/en unknown
- 2022-09-15 US US18/692,415 patent/US20250018050A1/en active Pending
- 2022-09-15 KR KR1020247012043A patent/KR20240058160A/ko active Pending
- 2022-09-15 MX MX2024003373A patent/MX2024003373A/es unknown
- 2022-09-15 AU AU2022345986A patent/AU2022345986A1/en active Pending
- 2022-09-15 JP JP2024517157A patent/JP2024534488A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534488A5 (https=) | ||
| IL311507A (en) | Dosing of muscle targeting complexes for the treatment of dystrophinopathy | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2025512468A5 (https=) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| US8992913B2 (en) | Antagonist antibodies against GDF-8 and uses therefor | |
| JP2024160045A5 (https=) | ||
| JP2024540199A5 (https=) | ||
| CN111527207B (zh) | GalNAc衍生物 | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| JP2024525612A5 (https=) | ||
| JP2024525611A5 (https=) | ||
| JP2023510350A5 (https=) | ||
| JP2024525610A5 (https=) | ||
| JP2025512469A5 (https=) | ||
| JP2024524222A5 (https=) | ||
| JP2025512469A (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 | |
| KR20230086663A (ko) | 대상체에서 생체분자를 발현하기 위한 시스템 및 방법 | |
| JP2009529915A5 (https=) | ||
| TW202535930A (zh) | 同功型選擇性抗-TGF-β 抗體及其使用方法 | |
| US20200318113A1 (en) | Polynucleotide conjugates and uses thereof | |
| JP2022527272A (ja) | 組み合わせ免疫調節及びその使用 | |
| US20260083854A1 (en) | Conjugates comprising bis-mspt linker | |
| WO2025242061A1 (zh) | 抗her2抗体药物偶联物治疗胆道癌的用途 | |
| JP2024532964A5 (https=) |